|
1
|
Druker BJ, Talpaz M, Resta DJ, Peng B,
Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R,
Ohno-Jones S and Sawyers CL: Efficacy and safety of a specific
inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid
leukemia. N Engl J Med. 344:1031–1037. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sawyers CL: Chronic myeloid leukemia. N
Engl J Med. 340:1330–1340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pavlu J, Szydlo RM, Goldman JM and
Apperley JF: Three decades of transplantation for chronic myeloid
leukemia: What have we learned? Blood. 117:755–763. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Howlader N, Noone AM, Krapcho M, Newman N,
Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2009 (Vintage 2009
Populations). National Cancer Institute; Bethesda, MD: Based on
November 2011 SEER data submission, posted to the SEER web site.
April. 2012, https://seer.cancer.gov/archive/csr/1975_2009_pops09/
|
|
5
|
Parker WT, Ho M, Scott HS, Hughes TP and
Branford S: Poor response to second-line kinase inhibitors in
chronic myeloid leukemia patients with multiple low-level
mutations, irrespective of their resistance profile. Blood.
119:2234–2238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Apperley JF: Chronic myeloid leukaemia.
Lancet. 385:1447–1459. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedman AD: C/EBPα in normal and
malignant myelopoiesis. Int J Hematol. 101:330–341. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeisig BB, Kulasekararaj AG, Mufti GJ and
So CW: SnapShot: Acute myeloid leukemia. Cancer Cell.
22:698.e12012. View Article : Google Scholar
|
|
9
|
Bhattaram P, Penzo-Méndez A, Sock E,
Colmenares C, Kaneko KJ, Vassilev A, Depamphilis ML, Wegner M and
Lefebvre V: Organogenesis relies on SoxC transcription factors for
the survival of neural and mesenchymal progenitors. Nat Commun.
1:92010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Song G, Wang L, Bi K and Jiang G:
Regulation of the C/EBPα signaling pathway in acute myeloid
leukemia (Review). Oncol Rep. 33:2099–2106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Alberich-Jorda M, Amabile G, Yang
H, Staber PB, Di Ruscio A, Welner RS, Ebralidze A, Zhang J,
Levantini E, et al: Sox4 is a key oncogenic target in C/EBPα mutant
acute myeloid leukemia. Cancer Cell. 24:575–588. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuwahara M, Yamashita M, Shinoda K,
Tofukuji S, Onodera A, Shinnakasu R, Motohashi S, Hosokawa H, Tumes
D, Iwamura C, et al: The transcription factor Sox4 is a downstream
target of signaling by the cytokine TGF-β and suppresses TH2
differentiation. Nat Immunol. 13:778–786. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aue G, Du Y, Cleveland SM, Smith SB, Davé
UP, Liu D, Weniger MA, Metais JY, Jenkins NA, Copeland NG and
Dunbar CE: Sox4 cooperates with PU.1 haploinsufficiency in murine
myeloid leukemia. Blood. 118:4674–4681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sandoval S, Kraus C, Cho EC, Cho M, Bies
J, Manara E, Accordi B, Landaw EM, Wolff L, Pigazzi M and Sakamoto
KM: Sox4 cooperates with CREB in myeloid transformation. Blood.
120:155–165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vervoort S, van Boxtel R and Coffer PJ:
The role of SRY-related HMG box transcription factor 4 (SOX4) in
tumorigenesis and metastasis: Friend or foe? Oncogene.
32:3397–3409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jafarnejad SM, Ardekani GS, Ghaffari M and
Li G: Pleiotropic function of SRY-related HMG box transcription
factor 4 in regulation of tumorigenesis. Cell Mol Life Sci.
70:2677–2696. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ramezani-Rad P, Geng H, Hurtz C, Chan LN,
Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, et
al: SOX4 enables oncogenic survival signals in acute lymphoblastic
leukemia. Blood. 121:148–155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Suknuntha K, Ishii Y, Tao L, Hu K,
McIntosh BE, Yang D, Swanson S, Stewart R, Wang JY, Thomson J and
Slukvin I: Discovery of survival factor for primitive chronic
myeloid leukemia cells using induced pluripotent stem cells. Stem
Cell Res. 15:678–693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bauer S, Buchanan S and Ryan I: Tyrosine
kinase inhibitors for the treatment of chronic-phase chronic
myeloid leukemia: Long-term patient care and management. J Adv
Pract Oncol. 7:42–54. 2016.PubMed/NCBI
|
|
21
|
Porse BT, Bryder D, Theilgaard-Mönch K,
Hasemann MS, Anderson K, Damgaard I, Jacobsen SE and Nerlov C: Loss
of C/EBPα cell cycle control increases myeloid progenitor
proliferation and transforms the neutrophil granulocyte lineage. J
Exp Med. 202:85–96. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus
ML, Dayaram T, Owens BM, Shigematsu H, Levantini E, Huettner CS,
Lekstrom-Himes JA, et al: Enhancement of hematopoietic stem cell
repopulating capacity and self-renewal in the absence of the
transcription factor C/EBP alpha. Immunity. 21:853–863. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baer C, Claus R, Frenzel LP, Zucknick M,
Park YJ, Gu L, Weichenhan D, Fischer M, Pallasch CP, Herpel E, et
al: Extensive promoter DNA hypermethylation and hypomethylation is
associated with aberrant microRNA expression in chronic lymphocytic
leukemia. Cancer Res. 72:3775–3785. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chim C, Wong AS and Kwong YL: Infrequent
hypermethylation of CEBPA promotor in acute myeloid leukaemia. Br J
Haematol. 119:988–990. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Annamaneni S, Kagita S, Gorre M, Digumarti
RR, Satti V and Battini MR: Methylation status of CEBPA gene
promoter in chronic myeloid leukemia. Hematology. 19:42–44. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thiel AT, Feng Z, Pant DK, Chodosh LA and
Hua X: The trithorax protein partner menin acts in tandem with EZH2
to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
Haematologica. 98:918–927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dedhia PH, Keeshan K, Uljon S, Xu L, Vega
ME, Shestova O, Zaks-Zilberman M, Romany C, Blacklow SC and Pear
WS: Differential ability of Tribbles family members to promote
degradation of C/EBPalpha and induce acute myelogenous leukemia.
Blood. 116:1321–1328. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fung TK, Leung AY and So CW: Sox4you: A
new player in C/EBPα leukemia. Cancer cell. 24:557–559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aue G, Du Y, Cleveland SM, Smith SB, Davé
UP, Liu D, Weniger MA, Metais JY, Jenkins NA, Copeland NG and
Dunbar CE: Sox4 cooperates with PU.1 haploinsufficiency in murine
myeloid leukemia. Blood. 118:4674–4681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Du Y, Spence SE, Jenkins NA and Copeland
NG: Cooperating cancer-gene identification through
oncogenic-retrovirus-induced insertional mutagenesis. Blood.
106:2498–2505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanfstein B, Shlyaknto V, Lauseker M,
Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U,
Schnittger S, et al: Velocity of early BCR-ABL transcript
elimination as an optimized predictor of outcome in chronic myeloid
leukemia (CML) patients in chronic phase on treatment with
imatinib. Leukemia. 28:1988–1992. 2014. View Article : Google Scholar : PubMed/NCBI
|
